<DOC>
	<DOCNO>NCT02583165</DOCNO>
	<brief_summary>To evaluate safety tolerability MEDI1873 adult subject select advance solid tumor</brief_summary>
	<brief_title>A Study Adult Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description>This first-time-in-human , Phase 1 , multicenter , open-label , single-arm dose-escalation study MEDI1873 evaluate safety , tolerability , pharmacokinetics , immunogenicity , pharmacodynamics anti-tumor activity adult subject advance solid tumor malignancy .</detailed_description>
	<criteria>All subject must consent provide archived tumor specimen Subjects must histologically cytologically confirm advanced solid tumor recurrent metastatic disease . At time Day 1 study , subject central nervous system ( CNS ) metastases must treat must asymptomatic Willingness provide pretreatment ontreatment biopsy . Adequate organ function Females childbearing potential nonsterilized male sexually active must use effective method contraception Known allergic reaction component MEDI1873 Concurrent enrollment another clinical study , unless observational clinical study followup period interventional study Receipt anticancer therapy within 4 week prior first dose MEDI1873 ; case mAbs , 6 week prior first dose MEDI1873 Any concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment . Receipt live , attenuated vaccine within 28 day prior first dose investigational product Unresolved toxicities prior anticancer therapy Any condition , opinion investigator sponsor , would interfere evaluation investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>immuno-oncology</keyword>
</DOC>